Status:

COMPLETED

Brain Clock and Insulin Resistance

Lead Sponsor:

Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)

Conditions:

Insulin Resistance

Type 2 Diabetes

Eligibility:

All Genders

25-65 years

Brief Summary

In this observational cohort study the investigators will determine the activity rhythm of the suprachiasmatic nucleus in humans with progressive stages of insulin resistance, using advanced functiona...

Detailed Description

Type 2 diabetes mellitus (T2DM) has an increasing worldwide incidence. Insulin resistance is a key pathophysiological process in the development of hyperglycemia in patients with T2DM. Disruption of c...

Eligibility Criteria

Inclusion

  • Group 1: obese people with normal insulin sensitivity
  • age 25-65 years
  • BMI\>30
  • fasting plasma insulin ≤62 pmol/L
  • fasting plasma glucose \<5.6 mmol/L
  • Homeostatic Model Assessment for Insulin Resistance (HOMA-IR) ≤ 4.5
  • Group 2: obese people with insulin resistance
  • age 25-65 years
  • BMI\>30
  • fasting plasma insulin \>62 pmol/L
  • not fulfilling the American Diabetes Association (ADA) criteria for type 2 DM
  • Group 3: obese subjects with overt type 2 DM
  • age 25-65 years
  • BMI\>30
  • diagnosis type 2 DM according to ADA criteria

Exclusion

  • An extreme chronotype (midpoint of sleep on free days (MSFsc) before 2:00 or after 6:00).
  • Active psychiatric disorder (including circadian rhythm sleep disorder) as defined in Diagnostic and Statistical Manual of Mental Disorders (DSM) 5
  • Disorders of the central nervous system (Early-onset dementia, stroke, epilepsy, Parkinson's disease, brain tumor)
  • Severe visual impairment (WHO classification)
  • Shift workers
  • Crossing \> 2 time zones in the 3 months before the study
  • Patients with type 2 DM receiving insulin treatment or glucagon-like peptide (GLP) 1 agonists
  • MRI contraindications

Key Trial Info

Start Date :

January 4 2023

Trial Type :

OBSERVATIONAL

Allocation :

ACTUAL

End Date :

November 1 2025

Estimated Enrollment :

28 Patients enrolled

Trial Details

Trial ID

NCT05314855

Start Date

January 4 2023

End Date

November 1 2025

Last Update

January 7 2026

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Amsterdam University Medical Centers, location AMC

Amsterdam, North Holland, Netherlands, 1105AZ

Brain Clock and Insulin Resistance | DecenTrialz